IMV (NASDAQ:IMV) Upgraded to Hold at Zacks Investment Research

IMV (NASDAQ:IMVGet Rating) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday, reports.

According to Zacks, “IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company’s pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada. “

Separately, Raymond James reduced their price objective on IMV from $1.75 to $1.50 and set a “market perform” rating on the stock in a research report on Friday, March 18th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from, the stock currently has a consensus rating of “Buy” and a consensus target price of $2.22.

IMV opened at $0.97 on Tuesday. The company has a market cap of $79.50 million, a P/E ratio of -1.89 and a beta of 1.33. The company has a current ratio of 5.01, a quick ratio of 5.01 and a debt-to-equity ratio of 0.90. The company’s 50 day moving average is $1.28 and its 200-day moving average is $1.32. IMV has a 1-year low of $0.90 and a 1-year high of $2.50.

IMV (NASDAQ:IMVGet Rating) last issued its earnings results on Thursday, March 17th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $0.04 million during the quarter. IMV had a negative net margin of 19,535.29% and a negative return on equity of 145.26%. During the same quarter in the prior year, the company earned ($0.11) EPS. On average, equities analysts forecast that IMV will post -0.45 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMV. Morgan Stanley grew its position in shares of IMV by 13,722.0% in the 2nd quarter. Morgan Stanley now owns 41,466 shares of the company’s stock valued at $91,000 after buying an additional 41,166 shares during the last quarter. Millennium Management LLC acquired a new position in shares of IMV in the 2nd quarter valued at about $69,000. Geode Capital Management LLC lifted its stake in shares of IMV by 44.7% in the 3rd quarter. Geode Capital Management LLC now owns 38,325 shares of the company’s stock valued at $63,000 after purchasing an additional 11,833 shares during the period. LexAurum Advisors LLC lifted its stake in shares of IMV by 69.5% in the 4th quarter. LexAurum Advisors LLC now owns 164,570 shares of the company’s stock valued at $201,000 after purchasing an additional 67,500 shares during the period. Finally, National Bank of Canada FI acquired a new position in shares of IMV in the 4th quarter valued at about $1,328,000. Hedge funds and other institutional investors own 13.03% of the company’s stock.

IMV Company Profile (Get Rating)

IMV Inc operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer.

Read More

Get a free copy of the Zacks research report on IMV (IMV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with's FREE daily email newsletter.